Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00824330
Other study ID # H08-02237
Secondary ID
Status Completed
Phase N/A
First received January 14, 2009
Last updated April 12, 2017
Start date January 2009
Est. completion date September 2015

Study information

Verified date April 2017
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Older persons with diabetes have a harder time maintaining blood pressure when standing up. When blood pressure drops when standing up, fainting may occur. This study will see how regular exercise can improve the ability of the body to keep blood pressure up when standing. We want to see how this improvement varies with a home-based walking program.


Description:

Detailed Summary

1. PURPOSE: Older adults with diabetes faint frequently, due to an impairment in the cardiovascular control mechanisms (arterial baroreceptor function, autonomic nervous system function and cerebral autoregulation) that prevent syncope. The purpose of this study is to examine the ability of a home based walking program to reverse these impairments.

2. HYPOTHESES: a) A home-based walking program will improve the compensatory cardiovascular responses that prevent syncope in older adults with Type 2 diabetes. A moderate, regular exercise program will:

- increase arterial baroreflex sensitivity

- increase heart rate variability (marker of autonomic nervous system function)

- decrease cerebrovascular resistance

- improve cerebral autoregulation during upright tilt. b) There will be relationship between the improvement in compensatory cardiovascular responses and regular exercise.

c) Design of more practicable training prescriptions than that used in a research setting.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date September 2015
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria:

- Type 2 diabetes for at least 5 years treated with diet alone or oral agents

- Nonsmoker for at least 5 years

- Subjects must be sedentary (as defined by no strength training and less than 30 minutes brisk walking/moderate exercise per week and no vigorous exercise in the preceding 6 months)

- All subjects will have a fasting glucose of <12 mM and a hemoglobin A1c < 8.5%

- Orthostatic hypotension defined as a decrease in systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg within 3 minutes of assuming an upright posture on the initial screening visit as per current American Academy of Neurology guidelines.

Exclusion Criteria:

- Abnormalities on complete blood count, electrolytes or creatinine, on resting ECG, treadmill exercise stress test

- Significant pulmonary, exercise-limiting orthopedic or neurological impairment

- Evidence of valvular disease, exercise-induced syncope, angina, arrhythmias or peripheral vascular disease

- Poor blood pressure control as defined as systolic blood pressure greater than or equal to 160 mm Hg or diastolic blood pressure greater than or equal to 90 mm Hg

- Total cholesterol/HDL cholesterol greater than or equal to 5.0 or LDL cholesterol greater than or equal to 4.21 mmol/L

- Peripheral neuropathy severe enough to cause discomfort (for safety reasons)

- Overt diabetic nephropathy excluding subjects with a urine albumin to creatinine ratio of greater than 2.0 in men or 2.8 in women

- Diabetic retinopathy

Study Design


Intervention

Behavioral:
Control Phase; Exercise Phase
After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.

Locations

Country Name City State
Canada Dr. Scott Lear's Lab, Simon Fraser University, Harbour Vancouver British Columbia
Canada VITALiTY Research Centre - VGH Research Pavilion Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pulse wave velocity (central and peripheral) Measured at Baseline, 3 months after control phase and after 3 months of Intervention phase
Primary Drop in middle cerebral artery velocity with upright tilting Measured at Baseline, 3 months after control phase and after 3 months of Intervention phase
Primary Drop in blood pressure with upright tilt Measured at Baseline, 3 months after control phase and after 3 months of Intervention phase
Primary Arterial baroreflex sensitivity Measured at Baseline, 3 months after control phase and after 3 months of Intervention phase
Secondary Fasting blood glucose, HgbA1C Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
Secondary VO2max Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
Secondary Dynamometry measures of muscle strength Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
Secondary Resting and maximal heart rate Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
Secondary Waist to hip ratio, BMI Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
Secondary Lean body mass/% fat Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
Secondary Catecholamines Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
Secondary Increase in Gosling's pulsatility index Measured at Baseline, 3 month after control phase and after 3 months of Intervention phase.
See also
  Status Clinical Trial Phase
Completed NCT05594446 - Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
Completed NCT03975309 - DHS MIND Metabolomics
Completed NCT01855399 - Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes N/A
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05007990 - Caregiving Networks Across Disease Context and the Life Course
Active, not recruiting NCT04420936 - Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program N/A
Recruiting NCT03549559 - Imaging Histone Deacetylase in the Heart N/A
Completed NCT04903496 - Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
Completed NCT01437592 - Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects Phase 1
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT03390179 - Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Recruiting NCT05294822 - Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes N/A
Completed NCT04427982 - Dance and Diabetes/Prediabetes Self-Management N/A
Completed NCT02356848 - STEP UP to Avert Amputation in Diabetes N/A
Completed NCT03292185 - A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects Phase 1
Active, not recruiting NCT05477368 - Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes N/A
Completed NCT04496401 - PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus Phase 4